Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:37:39 ON 12 JUN 2006

=> file medline, biosis, wpids
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.42       0.42

FILE 'MEDLINE' ENTERED AT 12:38:49 ON 12 JUN 2006

FILE 'BIOSIS' ENTERED AT 12:38:49 ON 12 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIDS' ENTERED AT 12:38:49 ON 12 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s ANG-1
L1         1700 ANG-1

=> s l1 and (ECM-binding domain)
L2            1 L1 AND (ECM-BINDING DOMAIN)

=> d l2 ti abs ibib tot

L2   ANSWER 1 OF 1  WPIDS  COPYRIGHT 2006 THE THOMSON CORP on STN
TI   New pharmaceutical composition comprises a pharmaceutical carrier and an
     amount of an extracellular matrix (ECM)-binding fragment of Ang-
     1 protein or a mutant Ang-1, useful for
     treating, e.g. cancer, vascular disease, or ischemia.
AN   2004-653413 [63]   WPIDS
AB   WO2004076650 A UPAB: 20041001
     NOVELTY - A pharmaceutical composition comprising a pharmaceutical carrier
     and an amount of an extracellular matrix (ECM)-binding fragment of
     Ang-1 protein or a mutant Ang-1, is
     new.
          DETAILED DESCRIPTION - A pharmaceutical composition comprises a
     pharmaceutical carrier and:
          (a) an amount of an ECM-binding fragment of Ang-1
     protein comprising 20-42 amino acids (SEQ ID NO. 1-4), or its homologous
     peptide and/or a vector comprising a nucleic acid molecule that encodes an
     ECM-binding fragment of Ang-1 protein;
          (b) an amount of a non-ECM binding fragment of Ang-
     1 protein that comprises a modification in an ECM-
     binding domain of Ang-1, where the
     modification reduces the binding of Ang-1 to an ECM
     and/or a vector comprising a nucleic acid molecule that encodes a non-ECM
     binding fragment of Ang-1 protein that comprises a
     modification in an ECM-binding domain of
     Ang-1, where the modification reduces the binding of
     Ang-1 to the ECM;
          (c) an amount of a proteolytic resistant fragment of Ang-
     1 protein that comprises a modification in a proteolytic domain of
     Ang-1, where the modification inhibits the proteolysis
     of Ang-1 and/or a vector comprising a nucleic acid
     molecule that encodes a proteolytic resistant fragment of Ang-
     1 protein that comprises a modification in a proteolytic domain of
     Ang-1, where the modification inhibits the proteolysis
     of Ang-1;
          (d) an mount of a mutant Ang-1 which retain their
     angiogenesis promoting activity but have reduced or inactive ECM binding
     or its homologous peptide or mutant versions of Ang-1
```

or a homologous peptide and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes a mutant **Ang-1** which retain their angiogenesis promoting activity but have reduced or inactive ECM binding or a homologous peptide or mutant versions of **Ang-1**;

(e) an amount of a mutant **Ang-1** which retain their angiogenesis promoting activity but which is not cleaved into an antagonist fragment or a homologous peptide and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that a mutant **Ang-1** which retain their angiogenesis promoting activity but has not cleaved into a antagonist fragment or a homologous peptide; or

(f) an amount of an **Ang-1** fragment with antagonist activity and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of an **Ang-1** fragment with antagonist activity.

INDEPENDENT CLAIMS are also included for:

(1) a method of treating an individual suspected of having coronary artery disease, vascular disease or a condition involving ischemia;

(2) a method of promoting angiogenesis, endothelial survival and maintaining vascular integrity in an individual;

(3) a method of treating an individual suspected of having a disease related to lack of blood vessels to effectively promote angiogenesis in the patients with the diseases related to lack of blood vessels such as ischemia in hearts and limbs;

(4) a method to reduce stroke, heart attack, blood vessel blockage, hemorrhage, artherosclerosis risk by maintaining the health and integrity of blood vessels;

(5) a method to assist the recovery of the patients who had stroke and the angioplasty procedure by promoting the growth/survival of endothelial cells and establish endothelial monolayer and inhibit excessive inflammation, hemorrhage, and proliferation of vascular smooth muscle;

(6) a method to treat patients with restenosis by inhibiting re-closure of blood vessel after inserting stents into blood vessels;

(7) a method to make stable and functional artificial blood vessels comprising using the composition above;

(8) a method of identifying compounds that modulates binding of **Ang-1** to ECM;

(9) a method of treating an individual suspected of having cancer;

(10) a method of preventing diabetes and/or arthritis in an individual suspected of being at risk of developing diabetes or arthritis;

(11) a fusion protein comprising:

(a) an ECM binding motif SEQ ID NO. 1-4 and a biologically active non-**Ang-1** protein;

(b) a non-ECM binding fragment of **Ang-1** and a biologically active non-**Ang-1** protein; or

(c) SEQ ID NO. 1-12 and non-**Ang-1** protein;

(12) a method of diagnosing an elevated probability of metastatic disease following tumor removal or elimination;

(13) a method of diagnosing and evaluating cancer in an individual for its probability of being an aggressive malignant cancer;

(14) a method of inhibiting Erk1/2 phosphorylation in a cell comprising administering the pharmaceutical composition;

(15) a method of inhibiting tumor angiogenesis in an animal; and

(16) a nucleic acid molecule encoding a fusion protein SEQ ID NO. 1-12 and non-**Ang-1** protein.

ACTIVITY - Cytostatic; Vasotropic; Antidiabetic; Antiarthritic; Cerebroprotective; Antiangiogenic.

No biological data given.

MECHANISM OF ACTION - Gene Therapy.

USE - The pharmaceutical composition is useful for treating diseases and disorders, e.g. cancer, coronary artery disease, vascular disease, ischemia, restenosis, diabetes, stroke, angiogenesis, or arthritis.

Dwg.0/8
ACCESSION NUMBER: 2004-653413 [63] WPIDS
DOC. NO. CPI: C2004-233867
TITLE: New pharmaceutical composition comprises a pharmaceutical carrier and an amount of an extracellular matrix (ECM)-binding fragment of **Ang-1** protein or a mutant **Ang-1**, useful for treating, e.g. cancer, vascular disease, or ischemia.
DERWENT CLASS: B04 D16
INVENTOR(S): YU, Q
PATENT ASSIGNEE(S): (YUQQ-I) YU Q; (UYPE-N) UNIV PENNSYLVANIA
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004076650	A2	20040910	(200463)*	EN	114
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2004186054	A1	20040923	(200463)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004076650	A2	WO 2004-US6101	20040227
US 2004186054	A1 Provisional	US 2003-450582P	20030227
		US 2004-789222	20040227

PRIORITY APPLN. INFO: US 2003-450582P 20030227; US 2004-789222 20040227

```
=> e yu,q/au
E1            2     YU ZUXI/AU
E2            1     YU ZUYUAN/AU
E3            0 --> YU,Q/AU
E4            1     YUA/AU
E5            1     YUA L M/AU
E6            2     YUA LIHUA/AU
E7            2     YUA M/AU
E8            1     YUA X/AU
E9            1     YUABOV B M/AU
E10           1     YUABOV YU M/AU
E11           3     YUABOVA E YU/AU
E12           3     YUABOVA M G/AU
```

Refine Search

Search Results -

Terms	Documents
L7 and L6	0

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Monday, June 12, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=OR			
L8	L7 and l6	0	L8
L7	yu.in.	11653	L7
L6	L5 and l4	38	L6
L5	(TIE-2 ligand)	66982	L5
L4	Ang-1	210	L4
L3	L1 and (pharmaceutical composition)	1	L3
L2	L1 and composition	1	L2
L1	6441137.pn.	1	L1

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

First Hit

Search Results - Record(s) 1 through 10 of 38 returned.

☐ 1. Document ID: US 7056509 B2

L6: Entry 1 of 38 File: USPT Jun 6, 2006

US-PAT-NO: 7056509
DOCUMENT-IDENTIFIER: US 7056509 B2

TITLE: Antibody methods for selectively inhibiting VEGF

DATE-ISSUED: June 6, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030175276 A1	September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		US
Brekken; Rolf A.	Seattle	WA		US

US-CL-CURRENT: 424/145.1; 424/130.1, 424/133.1, 424/184.1, 530/387.1, 530/388.1, 530/388.15, 530/388.25, 530/809, 530/864, 530/865, 530/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 2. Document ID: US 7052695 B2

L6: Entry 2 of 38 File: USPT May 30, 2006

US-PAT-NO: 7052695
DOCUMENT-IDENTIFIER: US 7052695 B2

TITLE: Angiopoietins and methods of treating hypertension

DATE-ISSUED: May 30, 2006

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20030082177 A1	May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kalish; Susan Croll	Tarrytown	NY		US

US-CL-CURRENT: 424/178.1; 514/12, 530/388.22, 530/391.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

☐ 3. Document ID: US 7008781 B1

L6: Entry 3 of 38 File: USPT Mar 7, 2006

US-PAT-NO: 7008781
DOCUMENT-IDENTIFIER: US 7008781 B1

TITLE: Method of enhancing the biological activity of ligands

DATE-ISSUED: March 7, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Samuel	New York	NY		US
Gale; Nicholas W.	Tarrytown	NY		US
Yancopoulos; George D.	Yorktown Heights	NY		US
Stahl; Neil	Carmel	NY		US

US-CL-CURRENT: 435/69.7; 424/134.1, 424/192.1, 435/252.33, 435/254.2, 435/320.1, 435/348, 435/360, 435/365.1, 514/12, 514/2, 530/399, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 4. Document ID: US 6962802 B2

L6: Entry 4 of 38 File: USPT Nov 8, 2005

US-PAT-NO: 6962802
DOCUMENT-IDENTIFIER: US 6962802 B2

TITLE: Growth factor homolog ZVEGF4

DATE-ISSUED: November 8, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gilbert; Teresa	Seattle	WA		
Hart; Charles E.	Woodinville	WA		
Sheppard; Paul O.	Granite Falls	WA		
Gilbertson; Debra G.	Seattle	WA		

US-CL-CURRENT: 435/69.4; 435/320.1, 435/69.1, 530/350, 530/399, 536/23.1, 536/23.5, 536/23.51

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 5. Document ID: US 6958147 B1

L6: Entry 5 of 38 File: USPT Oct 25, 2005

US-PAT-NO: 6958147
DOCUMENT-IDENTIFIER: US 6958147 B1

TITLE: Use of VEGF-C to prevent restenosis

DATE-ISSUED: October 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alitalo; Kari	Espoo			FI
Yla-Herttuala; Seppo	Kuopio			FI
Hiltunen; Mikko O.	Kuopio			FI
Jeltsch; Markku M.	Helsinki			FI
Achen; Marc G.	North Melbourne			AU

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.21, 435/320.1, 435/325, 435/455, 435/69.1, 514/44, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 6. Document ID: US 6947845 B2

L6: Entry 6 of 38 File: USPT Sep 20, 2005

US-PAT-NO: 6947845
DOCUMENT-IDENTIFIER: US 6947845 B2

TITLE: Method of identifying molecules that bind to the large ribosomal subunit

DATE-ISSUED: September 20, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steitz; Thomas A.	Branford	CT		
Moore; Peter B.	North Haven	CT		
Ippolito; Joseph A.	Guilford	CT		
Ban; Nenad	Zurich			CH
Nissen; Poul	Aarhus			DE
Hansen; Jeffrey L.	Charleston	SC		

US-CL-CURRENT: 702/19; 702/20, 702/27

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Ima

---

☐ 7. Document ID: US 6943153 B1

L6: Entry 7 of 38 File: USPT Sep 13, 2005

US-PAT-NO: 6943153
DOCUMENT-IDENTIFIER: US 6943153 B1

TITLE: Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

DATE-ISSUED: September 13, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Manning, Jr.; William C.	Redwood City	CA		
Dwarki; Varavani J.	Pittstown	NJ		
Rendahl; Katherine	Berkeley	CA		
Zhou; Shangzhen	Alameda	CA		

Miller; Sheldon S.	Berkeley	CA
Wang; Fei	Albany	CA

US-CL-CURRENT: 514/44; 424/233.1, 424/93.21

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

---

☐ 8. Document ID: US 6943146 B2

L6: Entry 8 of 38 File: USPT Sep 13, 2005

US-PAT-NO: 6943146
DOCUMENT-IDENTIFIER: US 6943146 B2

TITLE: Method for promoting neovascularization

DATE-ISSUED: September 13, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jakubowski; Aniela	Arlington	MA		
Burkly; Linda	West Newton	MA		

US-CL-CURRENT: 514/12; 424/1.41, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

---

☐ 9. Document ID: US 6887468 B1

L6: Entry 9 of 38 File: USPT May 3, 2005

US-PAT-NO: 6887468
DOCUMENT-IDENTIFIER: US 6887468 B1

TITLE: Antibody kits for selectively inhibiting VEGF

DATE-ISSUED: May 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/130.1; 424/139.1, 424/143.1, 424/145.1, 530/388.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc | Ima

---

☐ 10. Document ID: US 6878729 B2

L6: Entry 10 of 38 File: USPT Apr 12, 2005

US-PAT-NO: 6878729
DOCUMENT-IDENTIFIER: US 6878729 B2

TITLE: Medicinal uses of dihydropyrazoles

DATE-ISSUED: April 12, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Almstead; Ji-In Kim	Holmdel	NJ		
Izzo; Nicholas John	Pittsburgh	PA		
Jones; David Robert	Milford	OH		
Kawamoto; Richard Masaru	Lebanon	OH		

US-CL-CURRENT: 514/341; 546/275.4

Terms	Documents
L5 and L4	38